An implanted pouch of insulin-making cells: where Sernova’s trial stands
On 14 May 2025 Sernova reported that 8 of 12 people in an early trial reached insulin independence using its implanted 'Cell Pouch' holding donor islet cells.
A company called Sernova is testing an implant it calls the Cell Pouch: a small device placed under the skin that is later filled with donor insulin-making cells, so the body can make its own insulin again. In an early trial, 8 of 12 people reached the point of not needing insulin injections. That is a genuinely encouraging number, but it is a small, early-stage study, the cells come from a limited supply of donors, and people still have to take anti-rejection drugs. It does not change type 1 care today.
- The Cell Pouch is an implant placed under the skin; the body grows a blood supply into it, then donor islet cells (insulin-making cells) are added.
- In an early trial, 8 of 12 people reached insulin independence, meaning they no longer needed insulin injections at that point.
- This is interim data from a small Phase 1/2 trial, the early stage that tests safety and whether the idea works at all.
- People in the trial still take anti-rejection drugs, so this suits only those for whom that trade-off makes sense.
- The cells come from deceased donors, a limited supply, which is one reason lab-grown cells are the bigger long-term goal.
What the Cell Pouch is, and the early numbers
The idea behind the Cell Pouch is to make an islet transplant more controlled. Instead of injecting insulin-making cells straight into the liver, as current transplants do, a small pouch is implanted under the skin first. The body treats it like any implant and grows blood vessels into it, and only then are the donor islet cells placed inside, into a spot that already has a blood supply waiting for them.
In May 2025 Sernova reported interim results from its early trial: 8 of 12 people had reached insulin independence so far, meaning that at that stage they no longer needed to inject insulin. For a device this new, that is a real signal the approach can work, and it is why the trial is being watched closely.
The catches behind an encouraging headline
Eight out of twelve sounds like a lot, and in a way it is, but the numbers are small and the trial is early. Phase 1/2 studies are designed to test safety and whether something does anything at all, not to prove it works for the wider population. Results from a dozen people can look very different once hundreds are involved, which is exactly why later, larger trials exist.
Two other limits matter. People in this trial still take anti-rejection drugs to stop the immune system attacking the transplanted cells, and those drugs carry their own risks, so this route makes sense only for people for whom that trade-off is worth it. And the cells come from deceased donors, of which there will never be enough to treat everyone with type 1. That donor limit is a big reason the wider field is chasing insulin-making cells grown in the lab. For UK readers, the honest timeline is that any of this reaching routine NHS care is years off, with larger trials first.